Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 6Leukemia, Myeloid, Acute 4Thyroid Neoplasms 2Neoplasms 2Hepatoblastoma 2Thyroid cancer, Hurthle cell 1Thyroid Diseases 1Squamous Cell Carcinoma of Head and Neck 1Rhabdomyosarcoma 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Melanoma 1Gastrointestinal Stromal Tumors 1Fibrolamellar hepatocellular carcinoma 1Desmoplastic Small Round Cell Tumor 1Carcinoma 1

Interventions

Sunitinib 5ripretinib 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Imatinib Mesylate 2Biopsy 2regorafenib 1binimetinib 1Temozolomide 1TAS-116 1Sorafenib 1Rogaratinib 1Poly(ADP-ribose) Polymerase Inhibitors 1Nivolumab 1Midazolam 1Ipilimumab 1CTLA-4 Antigen 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Gastrointestinal Stromal Tumors × Sorafenib × Clear all
NCT00265798 2026-04-28

Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate

National Cancer Institute (NCI)

Phase 2 Active not recruiting
38 enrolled 9 charts
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡